GlassScriptPhysician profile
Jeremy Tabak
NPI 1609862515
$9,107.75
in general payments reported to CMS, 2019-2025
32 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $528 · 2021: $1,290 · 2022: $1,236 · 2023: $991 · 2024: $1,599 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,645 · Education: $34.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.54 |
| Education | $34.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,472.25 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $2,215.84 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,020.90 | 2019-2025 | Ofev, Jascayd |
| Inspire Medical Systems, INC. | $646.90 | 2019-2025 | Inspire |
| Insmed, INC. | $463.64 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $438.28 | 2021-2025 | |
| Philips North America LLC | $280.41 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Amgen INC. | $277.18 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $263.39 | 2019-2022 | |
| Fisher & Paykel Healthcare INC | $211.96 | 2019-2025 | Fisher & Paykel Healthcare |
| Mylan Specialty L.P. | $129.82 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $108.73 | 2019-2020 | |
| Verona Pharma, INC. | $81.41 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $79.03 | 2022-2024 | Acthar |
| Baxter Healthcare | $68.81 | 2022-2025 | Hillrom - Volara System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.83 | 2019-2024 | Dupixent |
| Itamar Medical INC | $26.54 | 2022-2023 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $25.39 | 2021 | |
| Sanofi Pasteur INC. | $23.27 | 2019 | |
| Optinose US, INC. | $21.78 | 2025 | |
| Grifols USA, LLC | $19.02 | 2020 | |
| Vifor Pharma, INC. | $18.71 | 2024 | Zemaira |
| Electromed, INC. | $18.67 | 2025 | Smartvest |
| Circassia INC. | $18.52 | 2019 | |
| United Therapeutics Corporation | $18.38 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.90 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.50 | 2019 | |
| Advanced Respiratory, INC | $15.59 | 2019 | |
| Pfizer INC. | $14.77 | 2019 | |
| Resmed Corp | $14.16 | 2019 | |
| Merck Sharp & Dohme LLC | $13.31 | 2020 | |
| Cmp Pharma, INC. | $12.86 | 2023 | Tadliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Tabak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.